United States Alzheimer’S Disease Diagnostics Market Size By Diagnostics Test (PET, SPECT, Blood Based ELISA Test, CSF Assays), By End-User (Hospitals, Diagnostic Centers, Pharmaceutical Companies, Clinics, and Academic Research Centers), And Forecast
Published Date: August - 2024 | Publisher: MIR | No of Pages: 320 | Industry: latest updates trending Report | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationUnited States Alzheimer’S Disease Diagnostics Market Size And Forecast
The market size of the United States Alzheimer’s Disease Diagnostics Market stood at USD 1,211.63 Million in 2022 and is projected to reach USD 1,768.10 Million by 2030, growing at a CAGR of 6.50% from 2024 to 2030.
The growing elderly population worldwide is one of the main factors driving the market for diagnostics for Alzheimer’s disease. In Addition, the precision and reliability of diagnosing Alzheimer’s disease have increased due to the introduction of innovative imaging tools, genetic testing procedures, and biomarkers. These developments influence the use of diagnostic tools and tests in clinical practice. The United States report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.
United States Alzheimer’S Disease Diagnostics Executive Summary
The Alzheimer’s disease is a neurological disease that frequently begins with moderate symptoms before getting progressively worse. It is a kind of dementia that becomes worse over time and is characterized by a person’s ability to function independently in everyday activities while their cognitive, behavioural, and social abilities progressively decrease. Alzheimer’s disease affects language and thought-controlling regions of the brain.
Based on Diagnostic Type, the U.S. Alzheimer’s Disease Market has been segmented SPECT, Positron Emission Tomography, Blood based ELISA Test, CSF Assays, Others. The Positron Emission Tomography is holding the largest share of the market. Moreover, based on End User, the U.S. Alzheimer’s Disease Market has been segmented into Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, Academic Research Center. The Hospital segment is holding the highest market share.
Cognitive decline, memory loss, and behavioural abnormalities are symptoms of Alzheimer’s disease (AD), a progressive neural condition. Accurate and early diagnosis are more essential than ever as the prevalence of AD increases in the country. The growing elderly population worldwide is one of the main factors driving the market for diagnostics for Alzheimer’s disease. Most AD victims are older, and as life expectancy increases, more people become vulnerable to the disease. As the population ages, cognitive deficits become more common, making early and precise diagnosis crucial for prompt intervention and treatment.
Furthermore, AD prevalence has been rising rapidly, especially in rich countries. The prevalence of AD is rising due to some factors, including sedentary lifestyles, bad diets, and a lack of preventative measures. Due to the rise in occurrence, there is an increased need for efficient diagnostic techniques to detect diseases at their earliest stages, when treatment is most effective. In Addition, the precision and reliability of diagnosing Alzheimer’s disease have increased due to the introduction of innovative imaging tools, genetic testing procedures, and biomarkers. These developments influence the use of diagnostic tools and tests in clinical practice.
The price and accessibility of diagnostic techniques are two significant barriers to the market for Alzheimer’s disease diagnosis. Advanced imaging methods are costly and challenging to acquire in many hospital settings. Particularly in areas with low resources, high costs, and restricted availability, prevent widespread adoption and delay early diagnosis. Moreover, huge investments and the risk of failure can hamper market growth. Government programs, initiatives, or funds that promote innovation and market development for Alzheimer’s disease diagnostics provide market expansion prospects.
What's inside a
industry report?
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
United States Alzheimer’S Disease Diagnostics MarketSegmentation Analysis
The United States Alzheimer’S Disease Diagnostics Market is segmented based on Diagnostics Test, and End-User.
United States Alzheimer’S Disease Diagnostics Market, By Diagnostics Test
To Get a Summarized Market Report By Diagnostic Test-
So, when we look at the Diagnostic Test results, the market breaks down into a few key areasPET, SPECT, Blood Based ELISA Test, CSF Assays, and, of course, a catch-all "Others" category. Right now, the US Alzheimer’s Disease Diagnostics Market is really liking the PET segment. In fact, PET grabbed the biggest slice of the pie in 2022 with 35.67% – that's USD 378.76 Million! And it's expected to keep growing at around 5.92% annually. SPECT wasn't far behind as the second-largest market in 2022, bringing in USD 258.58 Million and projected to grow at a CAGR of 6.17%. But get thisCSF Assays is predicted to be the real speed demon, growing the fastest at a CAGR of 8.38%.
In Alzheimer’s disease (AD), positron emission tomography (PET) is a crucial diagnostic procedure. PET uses a radiotracer, a radioactive chemical that releases positrons, to see the metabolic activity in the brain. Fluorodeoxyglucose (FDG), which assesses glucose metabolism, is one of the radiotracers frequently employed in diagnosing AD. Reduced glucose metabolism in particular brain areas, notably the temporal and parietal lobes, is a symptom of AD. These metabolic anomalies may be found and differentiated between AD and other types of dementia using PET-FDG imaging. Early AD identification is essential for better symptom management and appropriate treatments.
Furthermore, PET scans using tau-specific radiotracers can be used to visualize tau protein clumps, a crucial pathogenic characteristic of AD. These tracers, including AV-1451, commonly called T807 or flortaucipir, attach only to the tau tangles in the brain. While used to stage diseases, monitor disease development, and assess the efficacy of experimental therapies that target tau, tau imaging sheds light on the degree and distribution of tau pathology.
United States Alzheimer’S Disease Diagnostics Market, By End-User
To Get a Summarized Market Report By Geography-Â
Based on End-User, the market is segmented into Hospitals, Diagnostic Centers, Pharmaceutical Companies, Clinics, and Academic Research Centers. The US Alzheimer’S Disease Diagnostics Market is experiencing a scaled level of attractiveness in the Hospitals segment. Hospitals accounted for the largest market share of 30.93% in 2022, with a market value of USD 328.40 Million, and is projected to grow at a CAGR of 5.85% during the forecast period. Diagnostic Centers were the second-largest market in 2022, Value of USD 298.02 Million in 2022; it is projected to grow at the highest CAGR of 7.68%.
People usually go to the hospital to get checked out for Alzheimer's. After that, doctors will suggest a treatment plan aimed at keeping them as comfortable and healthy as possible, all to give them better access to figuring out what's going on and how to deal with it. Hospitals have all sorts of fancy scanning equipment to help diagnose Alzheimer's. But here's the thingthere's no single test that tells you everything. Getting the full picture requires different approaches and tools, with help from specialists like neurologists, neuropsychologists, geriatricians, and geriatric psychiatrists. When these experts work together, it's easier to get an accurate diagnosis, plan the right therapy, and keep a close eye on how the patient is doing.
Key Players
The major players in the market are; GE Healthcare, Siemens Healthineers AG, F. Hoffmann-La Roche Ltd., Quanterix, Sysmex, Eli Lilly & Company, C2N Diagnostics, Randox, MagQu Co. Ltd., Neuro-Bio Ltd, Pre-Diagnostics AS, Fujirebio and others. This section provides company overview, ranking analysis, company regional and industry footprint, and ACE Matrix.
Company Market Ranking Analysis
To really understand who's leading the pack in Alzheimer's Disease Diagnostics, we dug deep into the top 3 companies. Our ranking isn't just a guess – we look at a bunch of stuff! We're talking about the power of a company's brand, their whole product lineup (all the different versions, specs, bells, and whistles, and even the price!), how big they are across different regions, how well their products are selling these days, and how much of the overall money they're grabbing. Right now, GE Healthcare, Siemens Healthineers AG, and F. Hoffmann-La Roche Ltd are the names you need to know. We also check out their product strategies, like the cool tech they're using and new moves they're making to get bigger, especially in the US and around the world. Finally, understanding their End-Users (that's Hospitals, Diagnostic Centers, Pharmaceutical Companies, Clinics, and Academic Research Centers) helps us see where they're strong and where they have a solid grip on the Alzheimer's Disease Diagnostics markets.
Company Regional/Industry Footprint
Our regional section tells you where companies are active geographically, showing their reach at a regional level and highlighting their sales network presence. For example, you'll see that GE Healthcare Company Inc. has a presence in the US. Then, the industrial footprint section gives you a cross-analysis of different industry areas and key players, painting a clearer picture of the company landscape related to the industries they focus on and the products they offer. We also break down each company's product portfolio, looking at how diversified they are and the total number of products or services they provide. Finally, we assess their geographic reach and market penetration by considering how well their products and services have taken hold in different geographical areas and industries.
Ace Matrix
This section of the report provides an overview of the company evaluation scenario in the Alzheimer’s Disease Diagnostics market. The company evaluation has been carried out based on the outcomes of the qualitative and quantitative analyses of various factors such as the product portfolios, technological innovations, market presence, revenues of companies, and the opinions of primary respondents.
Report Scope
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| STUDY PERIOD | 2019-2030 |
| BASE YEAR | 2022 |
| FORECAST PERIOD | 2024-2030 |
| HISTORICAL PERIOD | 2019-2021 |
| UNIT | Value (USD Million) |
| KEY COMPANIES PROFILED | GE Healthcare, Siemens Healthineers AG, F. Hoffmann-La Roche Ltd., Quanterix, Sysmex, Eli Lilly & Company, C2N Diagnostics, Randox, MagQu Co. Ltd., Neuro-Bio Ltd, Pre-Diagnostics AS, Fujirebio and others. |
| SEGMENTS COVERED | Diagnostics Test, and End-User. |
| CUSTOMIZATION SCOPE | Free report customization (equivalent up to 4 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope |
To Get Customized Report Scope-Â
Top Trending Reports
Research Methodology of Market Research
To know more about the Research Methodology and other aspects of the research study, kindly
Reasons to Purchase this Report
We dig deep into the market using both qualitative and quantitative methods, breaking it down by segments based on money matters and other stuff too. You'll get hard numbers – market value in USD Billion – for every little slice of the market. We'll pinpoint the region and segment set to explode with growth and become the top dog. Plus, we'll analyze how each region consumes the product/service and what's driving the market there. Get the scoop on the competitive scene, including who's on top, new launches, partnerships, expansions, and mergers & acquisitions from the last five years for the companies we profile. Speaking of profiles, they're packed with company overviews, insights, product comparisons, and SWOT analyses for the big players. We'll give you a look at the industry's present and future, highlighting the latest trends (like growth opportunities, drivers, challenges, and restraints in both emerging and established areas). We also break down the market with an in-depth Porter’s Five Forces analysis and provide insight into the market through a Value Chain analysis. Finally, we'll lay out the market dynamics and growth potential in the years ahead. Oh, and you get 6 months of support from our analysts after you buy.
Customization of the Report
• In case of any  please connect with our sales team, who will ensure that your requirements are met.
Related Reports
- Global Unified Monitoring Market Size By Component, By Deployment Mode, By Organization Size, By Geographic Scope And Fo...
- Global Efficacy Testing Market Size By Type, By Product & Service, By Application, By Geographic Scope And Forecast
- Anesthesia And Respiratory Devices Market By Product Type (Anesthesia Devices, Respiratory Devices), By End-User (Hospit...
- Global Animal Feed Ingredients Market Size By Product (Corn, Soybean Meal, Wheat, Fishmeal), By Application (Chickens, P...
- Global Spunbond Nonwovens Market Size By Function (Disposable, Durable), By Material Type (Polypropylene, Polyethylene, ...
- Global Angiography Equipment Market Size By Technology, By Procedure, By Application, By Geographic Scope And Forecast
Table of Content
To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )
List Tables Figures
To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy